Novo Nordisk A/S

NYSE:NVO Rapporto sulle azioni

Cap. di mercato: US$441.7b

Novo Nordisk Gestione

Gestione criteri di controllo 3/4

Novo Nordisk Il CEO è Lars Jorgensen, nominato in Jan2017, ha un mandato di 7.83 anni. possiede direttamente 0.002% delle azioni della società, per un valore di $ 9.23M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 6.7 anni.

Informazioni chiave

Lars Jorgensen

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO7.8yrs
Proprietà del CEO0.002%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Novo Nordisk: A GLP-1 Leader Faces Increasing Competition

Nov 06

Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued

Oct 21

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Aug 07

Novo Nordisk: Better Buying Opportunities Ahead

Jul 26

Novo Nordisk: Buy On Dips

Jul 04

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Jun 26

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Jun 18

Novo Nordisk: Considerable Growth Beyond Ozempic

May 27

The FTC Cracks Down On Novo Nordisk's Ozempic

May 03

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Apr 26

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Mar 07

Novo Nordisk, A Very Healthy Pharma Stalwart

Feb 28

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lars Jorgensen rispetto agli utili di Novo Nordisk?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Sep 30 2018n/an/a

DKK 38b

Jun 30 2018n/an/a

DKK 39b

Mar 31 2018n/an/a

DKK 39b

Dec 31 2017DKK 32mDKK 9m

DKK 38b

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Lars sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Lars è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Lars Jorgensen (58 yo)

7.8yrs

Mandato

DKK 60,100,000

Compensazione

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Lars Jorgensen
President7.8yrsDKK 60.10m0.0021%
$ 9.2m
Karsten Knudsen
Executive VP6.8yrsDKK 21.50m0.000010%
$ 44.2k
Henrik Wulff
Executive VP of Product Supplyno dataDKK 22.00m0.000060%
$ 265.0k
Camilla Sylvest
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Boardno dataDKK 21.30mNessun dato
Martin Lange
Executive VP of Development & Member of the Management Board3.8yrsDKK 20.90mNessun dato
Marcus Schindler
EVP of Research & Early Development3.7yrsDKK 20.90mNessun dato
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno dataNessun dato0.0011%
$ 5.0m
Douglas Langa
Executive VP of North America Operations & Member of Management Boardno dataNessun datoNessun dato
Ludovic Helfgott
Executive VPno dataNessun datoNessun dato
Tania Sabroe
Executive VP of Global People & Organisation and Member of Management Board1.7yrsNessun datoNessun dato
David Moore
Executive VP of Corporate Development & Member of Management Board1.7yrsNessun datoNessun dato
Jacob Martin Rode
Head of Investor Relationsno dataNessun datoNessun dato

3.8yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di NVO è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Sylvie Gregoire
Independent Director9.7yrsDKK 1.80mNessun dato
Helge Lund
Independent Chairman of the Board7.7yrsDKK 3.10mNessun dato
Henrik Poulsen
Vice Chairman of the Board3.7yrsDKK 2.00mNessun dato
Laurence Debroux
Independent Director5.7yrsDKK 2.00mNessun dato
Martin MacKay
Independent Director6.7yrsDKK 1.70mNessun dato
Andreas Fibig
Independent Director6.7yrsDKK 1.40mNessun dato
Kasim Kutay
Non-Independent Director7.7yrsDKK 1.20mNessun dato
Christina Law
Independent Director2.7yrsDKK 1.30mNessun dato
Liselotte Hyveled
Employee Representative Director2.7yrsDKK 800.00k0%
$ 0
Mette Jensen
Employee Non-Independent Representative Director6.7yrsDKK 1.20mNessun dato
Thomas Rantzau
Employee Representative Non-Independent Director6.8yrsDKK 1.00mNessun dato
Elisabeth Christensen
Employee Representative Director2.7yrsDKK 800.00kNessun dato

6.7yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NVO sono considerati esperti (durata media dell'incarico 6.7 anni).